Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06345703
Other study ID # NeuShen Therapeutics
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date April 30, 2024
Est. completion date February 2025

Study information

Verified date May 2024
Source NeuShen Therapeutics
Contact Chao Zhang, PhD
Phone 8613918282581
Email chao.zhang@neushen.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this clinical trial is to exlplore the profile of NS-136 in health conditions. The main questions it aims to answer are: - Is NS-136 safe and tolerable in heathy subjects under tested dosing regimen? - What is the pharmacokinectic profile of NS-136 in healthy subjects under tested dosing regimen?


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date February 2025
Est. primary completion date November 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria Study subjects must meet all of the following criteria for study entry: 1. Healthy males or females aged 18-65 years (inclusive), with a body mass index (BMI) between 18.00 and 32.00 kg/m2(inclusive); 2. Not participated in any other clinical trials within the past 30 days or 5 half-lives of other investigational drugs prior to the screening, whichever is longer; 3. For women of reproductive potential, a negative pregnancy test is required, and they must agree to use contraception (more details see Appendix 1) from the time of signing the informed consent form until at least 90 days after the last dose of investigational product. Male subjects must agree to use adequate contraception from the time of signing the informed consent form until at least 90 days after the last dose of investigational product, and donation of sperm or ova is prohibited during the entire study period; 4. In good health, determined by the investigator on the basis of medical history, physical examinations, vital signs, 12-lead electrocardiograms (12-ECGs), clinical laboratory tests (haematology, urinalysis, blood chemistry). Repeated examination is allowed once at investigator's discretion; 5. Full understanding of the purpose, nature, procedures of the study, and the potential adverse reactions. Subject voluntarily participates and signs the informed consent form before any study procedures begin. Exclusion Criteria Subjects who meet any of the following criteria will be excluded from study entry: 1. Individuals who are allergic to the investigational product or any of its components, or who are easily allergic at investigator's discretion; 2. Individuals who are intolerant to venipuncture/venous catheterization or blood fainting or needle phobia; 3. Positive results for hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (Anti-HCV), human immunodeficiency virus antibody (Anti-HIV) during the screening period; 4. Average daily smoking of more than 5 cigarettes in the 3 months prior to screening, or inability to stop using any tobacco products (including nicotine products) during the trial; 5. Excessive alcohol consumption or weekly alcohol intake exceeding 14 units of alcohol in the 4 weeks prior to screening (1 unit equals 10 grams of pure alcohol, alcohol content of different alcoholic beverages is indicated by volume ratio, approximately 1 alcohol unit is equal to 35 mL of 50° liquor or 350 mL of 5° beer), or unwillingness to stop drinking alcohol or consuming any products containing alcohol during the trial, or positive alcohol test upon screening and admission (repeated test is allowed once at investigator's discretion); 6. Excessive intake of tea, coffee, or caffeinated beverages (more than 8 cups/day, 1 cup = 250 mL) in the 3 months prior to screening, or inability to stop consuming any beverages or foods containing caffeine, any beverages or foods rich in purines, or grapefruit and other substances that may affect drug absorption, distribution, metabolism, or excretion during the trial; 7. History of drug abuse within the past year prior to the first dose, or positive results in a multi-drug urine screening test upon screening period and admission. Repeated test is allowed once at investigator discretion; 8. History of definite neurological or psychiatric disorders (including epilepsy, migraines, dementia, depression or bipolar disorder, schizophrenia, etc.); history of prolonged QTc interval; immunodeficiency or immunosuppressive diseases, malignant neoplastic diseases; chronic cardiovascular, hepatic, renal, endocrine, respiratory, hematological (including coagulation), digestive system diseases, cholecystectomy, Gilbert's Syndrome or resolved childhood asthma; 9. Underwent major surgery within the past 6 months prior to the first dose (such as coronary artery bypass grafting, hepatectomy, gynecological surgery, etc.); occurrence of acute neurological, digestive, respiratory, circulatory, endocrine, hematological, or other systemic diseases that may affect the absorption, distribution, metabolism, excretion, and safety evaluation of the investigational product within 3 months prior to screening judged by investigator; 10. Donated blood or experienced blood loss =400 mL within the 3 months prior to the first dose; difficulties in venous blood collection; planned blood donation during the study or within 1 month after the study; 11. Use of strong inhibitors or inducers of cytochrome P450 (CYP) 3A4 within 14 days prior to the administration of the investigational drug or anticipated use of strong CYP3A4 inhibitors or inducers during the study participation period; 12. Use of any prescription or non-prescription medications, including herbal and OTC medications within 14 days of dosing, with the exception of paracetamol (=2 g per day); 13. Receipt of vaccines within the 4 weeks prior to the first dose of the investigational product; 14. Cannot tolerate high-fat meals or have special dietary requirements, or cannot adhere to a standardized diet (only for subjects in the FE trial); 15. Other factors deemed unsuitable for participation in the trial by the investigator.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Placebo
NS-136 matching placebo
NS-136 tablet
Investigational product NS-136

Locations

Country Name City State
Australia CMAX Clinical Research Pty Ltd Adelaide South Australia

Sponsors (1)

Lead Sponsor Collaborator
NeuShen Therapeutics

Country where clinical trial is conducted

Australia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants with Treatment-Related Adverse Events for SAD, day 1-7; for MAD, day 1-26, for FE, day1-14
Primary Main pharmacokinetic parameters Vd/F for SAD, day 1-7; for MAD, day 1-26,
Primary Main pharmacokinetic parameters CL/F for SAD, day 1-7; for MAD, day 1-26,
Primary Main pharmacokinetic parameters t1/2 for SAD, day 1-7; for MAD, day 1-26,
Primary Main pharmacokinetic parameters Tmax for SAD, day 1-7; for MAD, day 1-26,
Primary Main pharmacokinetic parameters AUC0-8 for SAD, day 1-7; for MAD, day 1-26,
Primary Main pharmacokinetic parameters Cmax for SAD, day 1-7; for MAD, day 1-26,
See also
  Status Clinical Trial Phase
Completed NCT05483998 - A Study to Evaluate Single and Multiple Doses of TLC-2716 in Healthy Participants Phase 1
Recruiting NCT02235012 - Cognitive Biases Under Ketamine N/A
Recruiting NCT02417714 - Prospective Evaluation of Next Generation CT Reconstruction (NextGenIR)
Completed NCT05088343 - Effect of Hetrombopag on the Pharmacokinetics of Rosuvastatin in Healthy Subjects Phase 1
Completed NCT04418973 - Analysis of Breath Volatile Organic Compounds After Dyspnea Induced in the Healthy Subject. N/A
Not yet recruiting NCT06248801 - Vildagliptin and Metformin Tablets 50/1000 mg Relative to GALVUS MET (50mg/1000 mg) Tablets Phase 1
Terminated NCT04068259 - Single Ascending Dose Study of PBI-4547 in Healthy Subjects Phase 1
Completed NCT03279302 - Trial to Evaluate the PK Profile of Glepaglutide (ZP1848) After a Single IV and After Multiple SC Injections in Healthy Subjects Phase 1
Not yet recruiting NCT06233162 - Febuxostat 80 mg Tablets Relative to Feburic® 80 mg Tablets Phase 1
Recruiting NCT04159844 - Evaluation of the Stiffness and Pressure Applied on the Lower Leg by a New Compression Bandage on Healthy Subjects N/A
Completed NCT06137911 - Evaluation of Safety, Tolerability & Pharmacokinetics of JYP0061 in Healthy Adults. Phase 1
Completed NCT04849286 - Measurement of HTL0016878 in Cerebrospinal Fluid Phase 1
Not yet recruiting NCT06233227 - Dutasteride Soft Capsule 0.5 mg Relative to Avodart 0.5 mg Soft Capsule Phase 1
Completed NCT04096157 - A Study to Assess Isavuconazole Following a Single Dose of Isavuconazonium Sulfate Intravenous Solution Via Nasogastric (NG) Tube Compared to a Single Dose of Oral Capsules Under Fasting Conditions in Healthy Participants Phase 1
Completed NCT01200368 - Trial Evaluating a 13-valent Pneumococcal Conjugate Vaccine Given With Diphtheria, Tetanus, and Acellular Pertussis Vaccine (DTaP) in Healthy Japanese Infants Phase 3
Recruiting NCT05805033 - Peri-Implant Soft Tissue Integration in Humans: Influence of Material N/A
Completed NCT04027803 - Comparative Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of Single Intravenous Doses of BCD-148 and Soliris® Phase 1
Recruiting NCT03467880 - Multicenter Study of Impulse Oscillometry in Chinese N/A
Completed NCT02903095 - Single Ascending Dose Study of TD-1439 in Healthy Subjects Phase 1
Active, not recruiting NCT02341508 - A Phase 1a, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate Lpathomab in Healthy Volunteers Phase 1